About
Built for the people
commercializing science.
Vainture is a CelesiumAI Company based in Houston, Texas. We replace months of manual commercialization analysis with AI-driven evaluation — so research institutions and venture firms can make faster, better-evidenced decisions about what to fund.
Our Story
A CelesiumAI Company.
Vainture was founded in 2026 by Phillip Phan, founder of CelesiumAI, after years of watching exceptional science fail to reach patients or markets — not because the ideas were bad, but because institutional evaluation bottlenecks made them invisible or mis-prioritized.
The same discipline that makes investment committees effective — filter rigorously, de-risk what survives — had never been operationalized for the academic commercialization pipeline. Vainture is that system.
Built in partnership with Baylor College of Medicine and Houston's research ecosystem. Designed for the decision rooms where science meets capital.
What we build
Three components. One system.
Vainture is more than an evaluation tool. It is the operational layer between scientific discovery and venture formation.
01 — Evaluate
Filter to Fund Engine
Scientists submit ideas or paste existing IP. AI returns a structured Commercialization Viability Report scored across market, competitive, regulatory, investor, partner, and funding dimensions.
02 — Manage
Portfolio Dashboard
Institutional leadership sees the full innovation pipeline scored and ranked. Filter by therapeutic area, development stage, or recommendation. Make resource allocation decisions on evidence, not anecdote.
03 — Direct
Trend Intelligence
Market signals across therapeutic areas. VC deal activity, pharma pipeline gaps, active public funding programs. Steer research toward areas with the highest commercialization probability.
Who it's for
Built for the people commercializing science.
Research Institutions
Baylor College of Medicine, Rice University, MD Anderson, UH, UTHealth
Replace manual evaluation of invention disclosures. Move faster on the ones that matter, decline the ones that don't — with evidence.
Venture Firms
Seed and Series A biotech, medtech, digital health
See investment-ready opportunities surfaced from institutional pipelines. Use the same AI evaluation as part of due diligence.
Operators & Investors
Fund managers, tech-transfer leaders, research VPs
Benchmark your pipeline against therapeutic-area trends. Know which bets are supported by the market — and which aren't.
Talk with us.
Vainture is currently onboarding institutional partners and venture firms. If that's you, we'd like to hear what you're working on.
Request Access